Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Biomarkers
• Myocardial Infarction Research

Background:

• Ischemic/reperfusion injury can compromise reperfusion effectiveness in STEMI.
• High-mobility group box 1 (HMGB1) is released by necrotic cells and implicated in myocardial injury.
• HMGB1's role in myocardial ischemic/reperfusion injury warrants further investigation.

Purpose of the Study:

• To evaluate the association between plasma HMGB1 levels and patient outcomes.
• To determine if HMGB1 can serve as a prognostic biomarker in STEMI patients.
• To assess HMGB1 levels in STEMI patients treated with primary percutaneous coronary intervention.

Main Methods:

• 141 STEMI patients with LAD occlusion treated with PCI were included.
• Plasma HMGB1 levels were measured using enzyme-linked immunosorbent assay at admission.
• 42 healthy individuals served as control subjects for comparison.

Main Results:

• STEMI patients exhibited higher baseline HMGB1 levels than controls.
• Higher HMGB1 levels were observed in STEMI patients who died during follow-up.
• A doubling of HMGB1 concentrations independently increased mortality risk by 75% (HR 1.75).

Conclusions:

• Plasma HMGB1 levels are elevated in STEMI patients compared to healthy individuals.
• Elevated HMGB1 is independently associated with increased 10-month mortality in STEMI patients post-PCI.
• Plasma HMGB1 shows potential as a novel prognostic biomarker for STEMI.